Combined Modality Therapy For Breast Carcinoma Phase III

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Outcome of African American women with breast cancer in cooperative group clinical trials

JM Unger;S Green;KS Albain Breast Cancer in Women of African Descent, Ch. 11, pp 267-295, C. Williams et al. (eds.), Springer, printed in Netherlands

Adjuvant chemo and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827.

SE Rivkin;S Green;SJ Altman;JJ Costanzi;AB Cruz;C Giarritta;WR Jewell;RM O'Bryan Proc of the American Society of Clinical Oncology 20:27a(#105)

Adjuvant chemo and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827

SE Rivkin;S Green;SJ Altman;JJ Costanzi;AB Cruz;C Giarritta;WR Jewell;RM O'Bryan;CK Osborne Breast Cancer Research and Treatment 69(3):249(#252)

Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study.

SE Rivkin;S Green;J O'Sullivan;AB Cruz;MD Abeloff;WR Jewell;JJ Costanzi;WB Farrar;CK Osborne Journal of Clinical Oncology 14(1):46-51

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study.

SE Rivkin;S Green;B Metch;AB Cruz;MD Abeloff;WR Jewell;JJ Costanzi;WB Farrar;JP Minton;CK Osborne Classic Papers and Current Comments 1(1):120-128

One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: A Southwest Oncology Group study.

SE Rivkin;S Green;B Metch;WR Jewell;JJ Costanzi;SJ Altman;JP Minton;RM O'Bryan;CK Osborne Classic Papers and Current Comments 1(1):129-135

Ovarian ablation in early breast cancer: overview of the randomised trials

KS Albain;JJ Crowley;S Green;S Martino;CK Osborne;PM Ravdin The Lancet 348(9036):1189-1196

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study

SE Rivkin;S Green;B Metch;AB Cruz;MD Abeloff;WR Jewell;JJ Costanzi;WB Farrar;JP Minton;CK Osborne Journal of Clinical Oncology 12(10):2078-2085

One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: A Southwest Oncology Group study.

SE Rivkin;S Green;B Metch;WR Jewell;JJ Costanzi;SJ Altman;JP Minton;RM O'Bryan;CK Osborne JCO 11(9):1710-1716

Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: A pilot study.

KS Albain;S Green;M LeBlanc;S Rivkin;J O'Sullivan;CK Osborne Breast Cancer Research and Treatment 22:273-284

Prognostic significance of lymphocyte counts (LC) in primary breast cancer (PBC).

S Baumgaertel;R Livingston;S Rivkin;J O'Sullivan;S Green ASCO 11:83(#160)

Adjuvant combination chemotherapy (CMFVP) vs oophorectomy followed by CMFVP (OCMFVP) for postmenopausal women with ER+ operable breast cancer with positive (+) axillary lymph nodes: An Intergroup study.

S Rivkin;S Green;B Metch;A Cruz;D Tesh;J Glick;W Knight;CK Osborne ASCO 10:47(#64)

Age < 35 years is an adverse prognostic feature in premenopausal node-positive breast cancer patients (PTS) in Southwest Oncology Group studies.

K Albain;S Green;S Rivkin;K Osborne ASCO 9:35(#132)

Adjuvant combination chemotherapy (CMFV P) vs tamoxifen (TAM) vs CMFVP+TAM for postmenopausal women with ER+ operable breast cancer and positive axillary lymph nodes: An intergroup study.

S Rivkin;S Green;B Metch;A Cruz;R McDivitt;W Knight;J Glick;CK Osborne ASCO 9:24(#87)

Adjuvant chemotherapy for poor prognosis estrogen receptor negative stage II-III breast cancer; a comparison of one year vs two years CMFVP.

S Green;S Rivkin;B Metch;CK Osborne;A Cruz;S Balcerzak;R Stevens;J Costanzi ASCO 8:24(#88)

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women.

J Crowley;J Glick;J Godwin;CK Osborne The New England Journal of Medicine 319(26):1681-1692

Adjuvant chemotherapy for poor prognosis estrogen receptornegative stage II, III breast cancer one year versus two years CMFVP.

S Rivkin;S Green;B Metch;CK Osborne;WA Knight;R McDivitt;A Cruz;D Tesh;J Costanzi;S Balcerzak;R Stevens ASCO :#C-266

Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes

SE Rivkin;WA Knight III;A Cruz;M Foulkes;R McDivitt AACR #717

Adjuvant therapy of breast cancer: The Southwest Oncology Group experience

WA Knight III;SE Rivkin;H Glucksberg;MA Foulkes;JJ Costanzi;RL Stephens;JW Athens;RM O'Bryan Breast Cancer Res & Treat 3(Suppl 1):27-33

Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes

A Cruz;S Rivkin;WS Knight;R McDivitt;D Tesh;M Foulkes ASCO #C-383

Adjuvant chemohormonal therapy for operable breast cancer: A SWOG study

S Rivkin;WA Knight;M Foulkes Breast Cancer Res Treat 3:306

Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes

A Cruz;S Rivkin;WA Knight;R McDivitt;D Tesh;M Foulkes;JB Aust ASCO #C-317